Role of the activating mutation Val617Phe of Janus kinase 2 gene in myeloproliferative diseases and significance of its detection;A 2-es típusú Janus tirozin kináz Val617Phe aktiváló pontmutáció szerepe és kimutatásának jelentosége myeloproliferatív szindrómában

Orvosi Hetilap

Volumn 148, Issue 5, 2007, Pages 203-210

  Andrikovics, Hajnalka ^a,b   Szilvási, Anikó ^a   Meggyesi, Nóra ^a   Király, Viktória ^a   Halm, Gabriella ^a   Lueff, Sándor ^a   Nahajevszky, Sarolta ^a   Mikala, Gábor ^a   Sipos, Andrea ^a   Lovas, Nóra ^a   Csukly, Zoltán ^a   Mátrai, Zoltán ^a   Tamáska, Júlia ^a   Tordai, Attila ^a   Masszi, Tamás ^a  

^a Orszagos Gyogyintezeti Kozpont   (Hungary)

^b Hematológiai és Ossejt transzplantációs Osztály ^*  (Hungary)

Author keywords

Essential thrombocythaemia; Janus kinase 2; Myeloproliferative disorders; Polycythaemia vera; V617F

Indexed keywords

HEMOGLOBIN; JANUS KINASE 2; PHENYLALANINE; VALINE; JAK2 PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ACUTE LEUKEMIA; ADULT; AGED; ARTICLE; BLEEDING; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; FEMALE; GENE FREQUENCY; HEMOGLOBIN BLOOD LEVEL; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MOLECULAR GENETICS; MUTATIONAL ANALYSIS; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; PHENOTYPE; POINT MUTATION; POLYCYTHEMIA VERA; POLYMERASE CHAIN REACTION; SPLENOMEGALY; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; BIOPSY; BONE MARROW; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; MYELOFIBROSIS; PATHOLOGY; THROMBOCYTOSIS;

ADULT; AGED; BIOPSY; BONE MARROW; FEMALE; GENE EXPRESSION REGULATION; GENE FREQUENCY; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDERS; PHENOTYPE; PHENYLALANINE; POINT MUTATION; POLYCYTHEMIA VERA; POLYMERASE CHAIN REACTION; THROMBOCYTOSIS; VALINE;

EID: 34249744337     PISSN: 00306002     EISSN: 17886120     Source Type: Journal    
DOI: 10.1556/OH.2007.27860     Document Type: Article

References (34)

1. Antonioli, E., Guglielmelli, R, Pancrazzi, A. és mtsai: Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. Leukemia, 2005, 19, 1847-1849.
2. Baxter, E. J., Scott, L. M., Campbell, P. J. és mtsai: Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferatáve disorders. Lancet, 2005, 365, 1054-1061.
3. Borbenyi, Z.: Eosinophiliával járó kórképek. A hypereosinophil szindróma jellemzoi és kezelési lehetóségei. Orv. Hetil., 2005, 146, Suppl. 1, 911-916.
4. Briere, J. B.: Budd-Chiari syndrome and portal vein thrombosis associated with myeloproliferative disorders: diagnosis and management. Semin. Thromb. Hemost., 2006, 32, 208-218.
5. Campbell, P. J., Griesshammer, M., Dohner, K. és mtsai: V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. Blood, 2006, 107, 2098-2100.
6. Campbell, P. J., Scott, L. M., Buck, G. és mtsai: Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective smdy. Lancet, 2005, 366, 1945-1953.
7. Cheung, B., Radia, D., Pantelidis, P. és mtsai: The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia. Br. J. Haematol., 2006, 132, 244-245.
8. Cooh, J., DeAngelo, D.J., Gotlib, J., Stover, E. H. és mtsai: A tyrosine kinase created by fusion of the PDGFRα and FIPIL1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N. Engl. J. Med., 2003, 348, 1201-1214.
9. Demeter J., Tamáska J.: Polycythaemia vera. In Hematológiai betegségek atlasza. Szerk: Matolcsy A., Udvardy, M., Kopper, L. Medicina Könyvkiadó Rt., Budapest, 2006, 132-136.
10. Hughes, T., Branford, S.: Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia. Blood Rev,. 2006, 20, 29-41.
11. James, C., Ugo, V., Le Couedic, J. P. és mtsai: A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature, 2005, 434, 1144-1148.
12. Jelinek, J., Oki, Y., Gharibyan, V. és mtsai: JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood, 2005, 106, 3370-3373.
13. Jones, A. V., Kreil, S., Zoi, K. és mtsai: Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood, 2005, 106, 2162-2168.
14. Kajtár, B., Méhes, G., Jáksó, R és mtsai: A krónikus myeloid leukaemia citogenetikai és molekuláris monitorozása. Orv. Hetil., 2006, 147, 963-970.
15. Kralovics, R., Passamonti, F., Buser, A. S. és mtsai: A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med., 2005, 352, 1779-1790.
16. Levine, R. L., Loriaux, M., Huntly, B. J. és mtsai: The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood, 2005, 106, 3377-3379.
17. Levine, R. L., Wadleigh, M., Cools, J. és mtsai: Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis; Cancer Cell, 2005, 7, 387-397.
18. Matolcsy A.: Új szemlélet a krónikus myeloid leukaemia diagnosztikájában és terápiájának monitorozásában. Orv. Hetil., 2004, 145, 2603-2609.
19. Nelson, M. E., Steensma, D. P.: JAK2 V617F in myeloid disorders: what do we know now, and where are we headed? Leuk. Lymphoma, 2006, 47, 177-194.
20. Passamonti, F., Rumi, E., Pietra, D. és mtsai: Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. Blood, 2006, 107, 3676-3682.
21. Ridell, B., Carneskog, J., Wedel, H. és mtsai: Incidence of chronic myeloproliferative disorders in the city of Goteborg, Sweden 1983-1992. Eur. J. Haematol., 2000, 65, 267-271.
22. Scott, L. M., Campbell, R J., Baxter, E. J. és mtsai: The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders. Blood, 2005, 106, 2920-2921.
23. Sreter L.: Krónikus myeloproliferatáv kórképek. Orv. Hetil., 1998, 139, 1779-1783.
24. Steensma, D. P., Dewald, G. W., Lasho, T. L. és mtsai: The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. Blood, 2005, 106, 1207-1209.
25. Tefferi, A., Gilliland, D. G.: The JAK2 V617F tyrosine kinase mutation in myeloproliferative disorders: status report and immediate implications for disease classification and diagnosis. Mayo Clin. Proc., 2005, 80, 947-958.
26. Tefferi, A., Lasho, T. L., Schwager, S. M. és mtsai: The clinical phenotype of wild-type, heterozygous, and homozygous JAK2 V617F in polycythemia vera. Cancer, 2006, 106, 631-635.
27. Tefferi, A., Spivak, J. L.: Polycythemia vera: scientific advances and current practice. Semin Hematol., 2005, 42, 206-220.
28. Telek B., Batár P., Udvardy M. és mtsa: A krónikus neutrophil leukaemiáról saját tapasztalataink alapján. Orv. Hetil., 2006, 147, 827-830.
29. Thurmes, P. J., Steensma, D. P.: Elevated serum erythropoietin levels in patients with Budd-Chiari syndrome secondary to polycythemia vera: clinical implications for the role of JAK2 mutation analysis. Eur J Haematol., 2006, 77, 57-60.
30. Udvardy, M.: Krónikus myeloid leukémia. Orv. Hetil., 2005, 146, 243-247.
31. Udvardy M., Matolcsy A.: Essentialis thrombocythaemia. In Hematológiai betegségek atlasza. Szerk: Matolcsy A., Udvardy M., Kopper L. Medicina Könyvkiadó Rt., Budapest, 2006, 140-143.
32. Vardiman, J. W., Brunning, R. D., Harris, N. L.: Chronic myeloproliferative diseases In World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of Hematopoietic and Lymphoid Tissues. Szerk: Jaffee, E. S., Harris, N. L., Stein, H. és mtsa, IARC Press, Lyon, 2001, 16-43.
33. Wolanskyj, A. R, Lasho, T. L., Schwager, S. M. és mtsai: JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. Br. J. Haematol., 2005, 131, 208-213.
34. Zhao, R., Xing, S., Li, Z. és mtsai: Identification of an acquired JAK2 mutation in polycythemia vera. J. Biol. Chem., 2005, 280, 22788-22792.